Mumbai, April 21,2018: Pharma Major, Cipla Ltd ssaid that US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Company’s Indore formulations facility from April 2, 2018 till April 13, 2018.
This was in the normal course of business. There were no data integrity and or repeat observations.
The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.
United News of India
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…